Abstract
The objectives of this chapter are to examine the effects of drug treatments on four major immune-related diseases and to determine the nutritional consequences of the drug-disease interaction in adults living in developed countries. The diseases discussed include HIV infection, diabetes (type 1 and type 2), rheumatoid arthritis, and osteoporosis. Osteoporosis is included because of the role of the osteoclast, which is a macrophagederived cell involved in bone breakdown (1). Insulin is a significant enhancer of bone formation, and, therefore, osteoporosis is often a consequence of diabetes (2). Osteoporosis is also included after the discussion of rheumatoid arthritis (RA) because the major drug class used to treat RA, glucocorticoids, is a known cause of secondary osteoporosis (3–5). Finally, organ transplant-associated osteoporosis demonstrates the links between a medical event (transplantation), immunotherapy, and nutritional effects (6,7).
Keywords
- Rheumatoid Arthritis
- Bone Mineral Density
- Hormone Replacement Therapy
- Cytotoxic Drug
- Secondary Osteoporosis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Dev Comp Immunol 1997;21:487–499.
Beers MH, Berkow R. Osteoporosis. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 469–473.
Bhattoa HP, Kiss E, Bettembuk P, Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int 2001;21: 97–102.
Bikle DD. Osteoporosis in gastrointestinal, pancreatic, and hepatic diseases. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic Press, New York, 2001, pp. 237–258.
Gennari C, Martini G, Nuti R. Secondary osteoporosis. Aging (Milano) 1998;10:214–224.
Goldring SR. Osteoporosis associated with rheumatologic disorders. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic Press, New York, 2001, pp. 351–362.
Leong GM, Centor JR, Henderson NK, Eisman JA. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic Press, New York, 2001, pp. 169–193.
Budavari S, O’Neil MJ, Smith A, Heckelman PE, Kinneart JF. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (12th ed.). Merck Professional Handbook, Whitehouse Station, NJ, 1996.
Beers MH, Berkow R. Nutrition: general consideration. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 1–23.
Beers MH, Berkow R. Factors affecting drug response. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 2574–2587.
Becker KL. Principals and Practice of Endocrinology and Metabolism (3rd ed.). Lippincott Williams & Wilkins, Philadelphia, PA, 2001.
Bowman BA, Russell RM. Present Knowledge in Nutrition (8th ed.). ILSI, Washington, DC, 2001.
Committee on Nutrition Services for Medicare Beneficiaries. Nutrition support. In: Institute of Medicine Committee on Nutrition Services for Medicare Beneficiaries (ed.). The Role of Nutrition in Maintaining Health in the Nation’s Elderly. National Academy Press, Washington, DC, 2002, pp. 173–212.
Alonso-Aperte E, Varela-Moreiras G. Drugs-nutrient interactions: a potential problem during adolescence. Eur J Clin Nutr 2000;54(Suppl 1):S69-S74.
Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD. Phenytoin and folic acid: individualized drug-drug interaction. Ther Drug Monit 1983;5:395–399.
Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000;18:1780–1799.
Brown RO, Dickerson RN. Drug-nutrient interactions. Am J Manag Care 1999;5:345–352.
Gauthier I, Malone M, Lesar TS, Aronovitch S. Comparison of programs for preventing drug-nutrient interactions in hospitalized patients. Am J Health Syst Pharm 1997;54:405–411.
Maka DA, Murphy LK. Drug-nutrient interactions: a review. AACN Clin Issues 2000;11:580–589.
Murray JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietitian. J Am Diet Assoc 1991;91:66–70, 73.
Roe DA. Drug and Nutrient Interaction (5th ed.). The American Dietetic Association, 1994.
Thomas JA. Drug-nutrient interactions. Nutr Rev 1995;53:271–282.
Thomas JA, Burns RA. Important drug-nutrient interactions in the elderly. Drugs Aging 1998;13: 199–209.
Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. Am Fam Physician 1991;44: 1651–1658.
Utermolen V. Diet, nutrition, and drug interactions. In: Shils ME, Olson JA, Shine M, Ross AC (eds.). Modern Nutrition in Health and Disease. Lippincott Williams & Wilkins, New York, 1999, pp. 1619–1641.
Parker P. Impact of nutritional status on immune integrity. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principals and Practice. Humana, Totowa, NJ, 2000, pp. 147–156.
Vellas BJ, Garry PJ. Aging. In: Bowman BA, Russell RM (eds.). Present Knowledge in Nutrition. ILSI, Washington, DC, 2001, pp. 439–446.
Meskin MS. Type 2 diabetes mellitus in the elderly. Nutr M D 2000;26:4.
Beisel WR. AIDS. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principals and Practice. Humana, Totowa, NJ, 2000, pp. 389–401.
Gerrior J, Wanke C. Nutrition and immunodeficiency syndromes. In: Coulston AM, Rock CL, Monsen ER (eds.). Nutrition in the Prevention and Treatment of Disease. Academic, New York, 2001, pp. 741–750.
Cunningham-Rundles S. Trace element and mineral nutrition in HIV infection and AIDS: implications for host defense. In: Bogden JD, Klevay LM (eds.). Clinical Nutrition of the Essential Trace Elements and Minerals. Humana, Totowa, NJ, 2000, pp. 333–351.
Beers MH, Berkow R. Human immunodeficiency virus infection. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 1312–1323.
Sinclair AJ, Barnett AH, Lunec J. Free radicals and antioxidant systems in health and disease. Br J Hosp Med 1990;43:334–344.
Sifton DW. Physicians’ Desk Reference (55th ed.). Medical Economics Company, Inc., Montvale, NJ, 2001.
Baum C, Moxon D, Scott M. Gastrointestinal disease. In: Bowman BA, Russell RM (eds.). Present Knowledge in Nutrition. ILSI, Washington, DC, 2001, pp. 472–482.
Krensky AM, Storm TB, Bluestone JA. Immunomodulators: immunosuppressive agents, tolerogens, and immunomodulators. In: Hardman JG, Limbird LE, Gilman AG (eds.). The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2001, pp. 1463–1484.
Migueles SA, Tuazon CU. Endocrine disorders in human immunodeficiency virus infection. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1947–1958.
Kupka R, Fawzi W. Zinc nutrition and HIV infection. Nutr Rev 2002;60:69–79.
Tang AM, Graham NM, Chandra RK, Saah AJ. Low serum vitamin B-12 concentrations are associated with faster human immunodeficiency virus type 1 (HIV-1) disease progression. J Nutr 1997;127:345–351.
Beers MH, Berkow R. Disorders of carbohydrate metabolism. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 165–177.
Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann N Y Acad Sci 2001; 928:200–211.
Catanese VM, Kahn CR. Secondary form of diabetes mellitus. In: Becker KL (ed.). Principals and Practice of Endocrinology and Metabolism. . Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1327–1336.
Feldman EL, Stevens MJ, Russell JW, Greene DA. Diabetes neuropathy. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1391–1399.
Kahn CR. Etiology and pathogenesis of type 2 diabetes mellitus and related disorders. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1315–1319.
Kahn CR. Glucose homeostasis and insulin action. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1303–1307.
Krolewski AS, Warram JH. Natural history of diabetes mellitus. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1320–1327.
Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 2001;119:122–127.
Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455–461.
Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated betacell apoptosis. Diabetologia 2001;44:2115–2133.
Eliopoulos GM. Diabetes and infection. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &Wilkins, New York, 2001, pp. 1424–1428.
Preuss HG. Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence. J Am Coll Nutr 1997;16:397–403.
Hehenberger K, King GL. Cardiovascular complications of diabetes mellitus. In: Becker KL (ed). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1380–1391.
Strain JJ. Disturbances of micronutrient and antioxidant status in diabetes. Proc Nutr Soc 1991;50: 591–604.
Devaraj S, Jialal I. Oxidative stress and antioxidants in type 2 diabetes. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, pp. 117–125.
Kukreja A, Cost G, Marker J, et al. Multiple immunoregulatory defects in type 1 diabetes. J Clin Invest 2002;109:131–140.
Nolsoe RL, Kristiansen OP, Larsen ZM, Johannesen J, Pociot F, Mandrup-Poulsen T. Complete mutation scan of the human Fas ligand gene: linkage studies in Type I diabetes mellitus families. Diabetologia 2002;45:134–139.
Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr 1996;15:458–461.
Kyurkchiev S, Ivanov G, Manolova V. Advanced glycosylated end products activate the functions of cell adhesion molecules on lymphoid cells. Cell Mol Life Sci 1997;53:911–916.
Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract 2001;54(Suppl 2):S29-S33.
Gale EA. The discovery of type 1 diabetes. Diabetes 2001;50:217–226.
Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel NE. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001;34:645–650.
Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 1996;59:492–495.
Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841–1850.
Albright A. Nutrition management for type I diabetes. In: Coulston AM, Rock CL, Monsen ER (eds.). Nutrition in the Prevention and Treatment of Disease. Academic, New York, 2001, pp. 429–440.
Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Gilman AG (eds.). The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2001, pp. 1679–1714.
Weir GC. Insulin therapy and its complications. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1348–1360.
Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002;75:492–498.
Frier HI, Greene HL. Obesity and chronic disease impact of weight reduction. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, pp. 205–221.
Baldeon ME, Gaskins HR. Diabetes and immunity. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principles and Practice.Humana, Totowa, NJ, 2000, pp. 301–311.
de Luis DA, Fernandez N, Arranz M, Aller R, Izaola O. Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res Clin Pract 2002;55:185–190.
Defronao RH. Diabetic nephropathy. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1403–1418.
Eliopoulos GM. The diabetic foot. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1434–1438.
Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 2000;49:1033–1041.
Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000;49:32–38.
Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult.): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460–1467.
Rand LI. Diabetes and the eye. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1418–1424.
Ternand C. A changing diet for patients with diabetes. Nutr M D 2000;27:6.
Hendler SS, Rorvik D. Physicians’ Desk Reference for Nutritional Supplements. Medical Economics Company, Inc., Montvale, NJ, 2001.
Goldfine AB, Maratos-Flier E. Oral agents for the treatment of type 2 diabetes mellitus. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, Philadelphia, PA, 2001, pp. 1344–1348.
Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821–827.
Gordon FD, Falchuk KR. Gastrointestinal complications of diabetes. In: Becker KL(ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1399–1403.
Buysschaert M, Bobbioni E, Starkie M, Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group. Diabet Med 1999;16:147–153.
Cohen JA, Jeffers BW, Stabler S, Schrier RW, Estascio R. Increasing homocysteine levels and diabetic autonomic neuropathy. Auton Neurosci 2001;87:268–273.
Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med 2001;18:185–192.
Blom HJ. Diseases and drugs associated with hyperhomocysteinemia. In: Carmel R, Jacobsen DW (eds.). Homocysteine in Health and Disease. Cambridge University Press, New York, 2001, pp. 331–340.
Hovind P, Tarnow L, Rossing P, et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001;38:1376–1380.
Mutus B, Rabini RA, Staffolani R, et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001;44:979–982.
Scaglione L, Gambino R, Rolfo E, et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002;32:24–28.
Hoogeveen EK, Rothman KJ. Hyperhomocysteinemia, diabetes, and cardiovascular disease. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, 127–154.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40: 405–412.
Nath N, Chari SN, Rathi AB. Superoxide dismutase in diabetic polymorphonuclear leukocytes. Diabetes 1984;33:586–589.
Preuss HG. The insulin system: influence of antioxidants. J Am Coll Nutr 1998;17:101–102.
Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993;16:1433–1437.
Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care 1991;14:68–72.
Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997;16:404–410.
Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786–1791.
Beers MH, Berkow R. Diffuse connective tissue disease. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 416–423.
Mongey AB, Hess EV. Drug and environmental effects on the induction of autoimmunity. J Lab Clin Med 1993;122:652–657.
Newkirk MM, LePage K, Niwa T, Rubin L. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Mol Biol (Noisy-le-grand) 1998;44:1129–1138.
Meyer O. Atherosclerosis and connective tissue diseases. Joint Bone Spine 2001;68:564–575.
Langford CA, Klippel JH, Balow JE, James SP, Sneller MC., Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 1998;129:49–58.
Balint G, Gergely P Jr. Clinical immunotoxicity of antirheumatic drugs. Inflamm Res 1996;45(Suppl 2):S91-S95.
Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Sanchez-Andrade A, Gonzalez-Gay MA. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol 1997;36:1095–1099.
Axelrod L. Corticosteroid therapy. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, Philadelphia, PA, 2001, pp. 751–772.
Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. Ann Intern Med 1998;128:1021–1028.
Morgan SL, Baggott JE. Role of dietary folate and oral folate supplements in the prevention of drug toxicity during anifolate therapy for nonneoplastic disease. In: Bendich A, Butterworth CE Jr (eds.). Micronutrients in Health and in Disease Prevention. Marcel Dekker, Inc., New York, 1991, pp. 333–358.
Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM. Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum 2001;31:133–141.
Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM. Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum 2001;31:133–141.: http://www.enbrel.com. 2002.
Chan LN. Drug-nutrient interactions in transplant recipients. J Parenter Enteral Nutr 2001;25: 132–141.
de Sousa M. Circulation and distribution of iron: a key to immune interaction. In: Cunningham-Rundles S (ed.). Nutrient Modulation of the Immune Response, Marcel Dekker, Inc., New York, 1993.
Galperin C, Fernandes G, Oliveira RM, Gershwin ME. Nutritional modulation of autoimmune diseases. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principles and Practice. Humana, Totowa, NJ, 2000, pp. 313–328.
Belluzzi A. Polyunsaturated fatty acids and autoimmune diseases. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, pp. 271–287.
Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc 1996;127:370–377.
Marcus R, Feldman D, Kelsey J. Osteoporosis (volume I) (2nd ed.). Academic, New York, 2001.
Marcus R, Feldman D, Kelsey J. Osteoporosis (volume II) (2nd ed.). Academic, New York, 2001.
Heaney RP. Osteoporosis: mineral, vitamins, and other micronutrients. In: Bendich A, Deckelbaum RJ (eds.). Preventive Nutrition: The Comprehensive Guide for Health Professionals. Humana, Totowa, NJ, 2001, pp. 271–292.
Orwoll ES. The prevention and therapy of osteoporsis in men. In: Orwoll ES (ed.). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic, New York, 1999, pp. 553–569.
Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247–1255.
Ebeling PR. Secondary causes of osteoporosis in men. In: Orwoll ES (ed.). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic, New York, 1999, pp. 483–514.
Heller HJ, Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neurol 2001;58:1352–1353.
Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998;128:829–832.
Kaye PS. Osteoporosis and fracture as a result of gastrointestinal and hepatic disorders. Practical Gastroenterol 2002;15–28.
Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369–1374.
Lappe JM, Tinley ST. Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked. Cancer 1998;83:830–834.
Hertz M, Juji T, Tanaka SMS. A therapeutic RANKL vaccine induces neutralizing anti-RANKL antibodies and prevents bone loss in overiectomized mice. J Bone Miner Res 2001;16:S222.
Marcus R. Use of estrogen for the prevention and treatment of osteoporosis. In: Rosen CJ (ed.). Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, 159–172.
Khosla S, Riggs BL. Treatment options for osteoporosis. Mayo Clin Proc 1995;70:978–982.
Guyatt GH. An introduction to clinical decision making in osteoporosis. In: Rosen CJ (ed.). Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, pp. 145–149.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
Fleisch H. Basic biology of bisphosphonates. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume I). Academic, New York, 2001, pp. 449–467.
Marcus R. Agents affecting calcification and bone turnover. In: Hardman JG, Limbird LE, Gilman AG (eds.). The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2001, pp. 1715–1743.
Colman E, Hedin R, Swann J, Orloff D. A brief history of calcitonin. Lancet 2002;359:885–886.
Hoff AO, Cote GJ, Gagel RF. Calcitonin. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume I). Academic, New York, 2001, pp. 247–255.
Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001;86:3618–3628.
Bilezikian JP, Silverberg SJ. The role of parathyroid hormone and vitamin D in the pathogenesis of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic, New York, 2001, pp. 71–84.
Nissenson RA. Parathyroid hormone and parathyroid hormone-related protein. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume I). Academic, New York, 2001, pp. 221–246.
Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153–164.
Cassidy JT, Hillman LS. Abnormalities in skeletal growth in children with juvenile rheumatoid arthritis. Rheum Dis Clin N Am 1997;23:499–522.
Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483–1490.
Reid IR. Glucocorticoids and osteoporosis. In: Orwoll ES (ed.). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic, New York, 1999, pp. 417–436.
Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:279–298.
Silverberg MS, Steinhart AH. Bone density in inflammatory bowel disease. Clin Pers Gastroenterol 2000;117–124.
Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002;73:547–552.
Marcus R. Calcium as a primary treatment and prevention modality for osteoporosis. In: Rosen CJ (ed.). Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, pp. 151–158.
Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995;98:331–335.
Stock JL. Drug therapy. In: Rosen CJ, ed. Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, pp. 173–187.
Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998;67:18–24.
Coulston AM. Nutritional management for type 2 diabetes. In: Coulston AM, Rock CL, Monsen ER (eds.). Nutrition in the Prevention and Treatment of Disease. Academic, New York, 2001, pp. 441–452.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bendich, A., Zilberboim, R. (2004). Use of Drugs that Affect Nutrition and Immune Function. In: Hughes, D.A., Darlington, L.G., Bendich, A. (eds) Diet and Human Immune Function. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-652-2_22
Download citation
DOI: https://doi.org/10.1007/978-1-59259-652-2_22
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-422-7
Online ISBN: 978-1-59259-652-2
eBook Packages: Springer Book Archive